Patient perceptions of the use of medical marijuana in the treatment of pain following musculoskeletal trauma. A survey of patients at two trauma centers in Massachusetts.

Marilyn Heng, MD, MPH, FRCSC Harvard Medical School Orthopedic Trauma Initiative Massachusetts General Hospital, Department of Orthopaedic Surgery Boston, MA mheng@partners.org

Michael F. McTague, MPH Harvard Medical School Orthopedic Trauma Initiative Brigham and Women's Hospital, Department of Orthopedic Surgery Boston, MA mmctague@partners.org

Robert C. Lucas, BA Harvard Medical School Orthopedic Trauma Initiative Massachusetts General Hospital, Department of Orthopaedic Surgery Boston, MA boblucas26@gmail.com

Mitchel B. Harris, MD Harvard Medical School Orthopedic Trauma Initiative Brigham and Women's Hospital, Department of Orthopedic Surgery Boston, MA mbharris@partners.org

Mark S. Vrahas, MD Harvard Medical School Orthopedic Trauma Initiative Massachusetts General Hospital, Department of Orthopaedic Surgery Boston, MA Mark.Vrahas@cshs.org

Michael J. Weaver, MD Harvard Medical School Orthopedic Trauma Initiative Brigham and Women's Hospital, Department of Orthopedic Surgery Boston, MA mjweaver@partners.org

Corresponding Author:

Michael J. Weaver, MD 75 Francis St. Boston, MA 02115 P: 617-525-8088 F: 617-730-2818 mjweaver@partners.org

Conflicts of Interest and Source of Funding: No relevant conflicts of interest and no sources of funding to report.

Presented as a poster at the Annual Meeting of the Orthopedic Trauma Association, National Harbor, MD, 2016.

- 1 Abstract
- 2 **Objective:** The purpose of this study is to evaluate musculoskeletal trauma patients' beliefs
- 3 regarding the usefulness of marijuana as a valid medical treatment for post-injury and post-
- 4 operative pain and anxiety.
- 5 **Design:** Prospective survey
- 6 **Setting:** Two academic level 1 trauma centers
- 7 **Patients/Participants:** 500 patients in an orthopedic outpatient clinic
- 8 **Intervention:** Survey
- 9 **Main Outcome Measurements:**
- 1. Do patients believe that marijuana can be used as medicine?
- 2. Do patients believe that marijuana can help treat post-injury pain?
- 12 3. Are patients comfortable speaking with their healthcare providers about medical marijuana?
- 13 **Results:** The majority of patients felt that marijuana could be used to treat pain (78%, 390) and
- anxiety (62%, 309). Most patients (60%, 302) had used marijuana at least once previously, while
- only 14% reported using marijuana following their injury. Of those that used marijuana during
- their recovery, 90% (63/70) believed that it reduced symptoms of pain; and 81% (57/70)
- believed that it reduced the amount of opioid pain medication they used.
- 18 Conclusions: The majority of patients in this study believed that medical marijuana is a valid
- 19 treatment and that it does have a role in reducing post-injury and post-operative pain. Those
- 20 patients who used marijuana during their recovery felt that it alleviated symptoms of pain and
- 21 reduced their opioid intake. Our results help inform clinicians regarding the perceptions of
- trauma patients regarding the usefulness of marijuana in treating pain, and support further study
- 23 into the utility of medical marijuana in this population.

Level of Evidence: Prognostic Level II

Keywords: Marijuana; medical marijuana; post-operative pain; musculoskeletal trauma

Introduction

There has been significant debate in the United States about the utility of medical marijuana. Despite federal laws limiting the sale and distribution of marijuana, 25 states and the District of Columbia currently allow the prescription of marijuana for the treatment of medical conditions. Based on the 2013 National Survey on Drug Use and Health (NSDUH), the prevalence of current marijuana use in all adults aged 18 years and over was 7.6%. Marijuana is the most common illicit substance used in the US. It has been demonstrated that there is a higher odds of marijuana use in states with medicinal marijuana laws compared to the states that have not legalized it for medicinal use.

In animal models, there is evidence that marijuana exerts anti-nociceptive effects. 4,5,6 However, the effectiveness of marijuana in the management of pain in human subjects remains unclear and controversial. To date, the evidence investigating the use of marijuana for pain management has focused largely on chronic pain or neuropathic pain. A recent systematic review of randomized controlled trials for its use in chronic pain suggests it is safe and modestly effective. To our knowledge, there are no studies evaluating the perceptions of the musculoskeletal trauma population with regard to the utility of using marijuana in the management of post-injury and post-operative pain.

The primary purpose of this study is to evaluate musculoskeletal trauma patients' beliefs regarding the usefulness of marijuana as a valid medical treatment for post-injury and post-operative pain and anxiety. Secondly, we wish to establish if there is an association between

marijuana use post-injury and patient reported anxiety, symptoms of post-traumatic stress, and pain. We also seek to evaluate how many of our musculoskeletal trauma patients would be comfortable discussing marijuana use with their orthopaedic provider and moreover, how many of our patients are already utilizing marijuana during their recovery from injury.

Materials and Methods

We performed a prospective study of patients presenting to our trauma clinics at 2 ACS level 1 trauma centers in Massachusetts, a state with recently passed medical marijuana legislation. Patients were approached to complete a survey if they were between 1 and 6 months from either a musculoskeletal injury (treated with or without surgery) and were over the age of 18. 538 patients were approached to take the survey. There were 500 patients who successfully completed the survey, yielding a response rate of 93% (Figure 1).

The survey consisted of 35 questions (Appendix A). Participants were asked demographic and injury questions as well as about their perceptions of the validity of the use of marijuana in the treatment of medical conditions, pain, and anxiety. We also asked patients about any history of marijuana use, and specifically if they used it during their recovery. Of the patients who responded affirmatively that they used marijuana during their recovery, we asked them about their perception of whether marijuana contributed to an improvement in their pain and whether it decreased their need for opioid pain medication.

Patients were administered the PROMIS SF v1.0-Anxiety 4a instrument to evaluate their feeling of anxiety and worries.⁸ For PROMIS instruments, the US population norm is a score of 50 with a standard deviation of 10. To evaluate catastrophic thinking regarding pain, patients were administered the Pain Catastrophizing Scale (PCS).⁹ This is a 13 item instrument validated to identify patients with increased worries and problems coping with pain. Scores are summed,

and using a cut-off score of 30, respondents were classified as either having a clinically relevant level of pain catastrophizing (score ≥30) or not (score <30). Patients were also administered the Short Screening Scale for DSM-IV Post-Traumatic Stress Disorder (PTSD) test, a 7 item survey of yes-no questions. Patients who respond with yes to 4 or more questions are considered positive, demonstrating sings and symptom of PTSD and likely to suffer from PTSD.

Survey responses were collected directly into a REDCap database. Statistical analysis was performed in R 3.2.2.¹¹ Multiple logistic regression analysis was performed to evaluate the association of age, sex, type of injury, and the need for surgery as independent predictors of a patient's likelihood to believe that marijuana can be used as a medicine, can be helpful in treating pain, or can help to treat anxiety.

Results

A total of 500 patients completed the survey. Fifty percent (250) of the respondents were female. The median age was 55 years old, range 18 to 93 (Figure 2). Thirty-one percent (153) of patients had an injury that was treated non-operatively, while 69% (347) had surgery to treat their injury. Injury characteristics are presented in Table 1.

The majority of patients, 81% (405), believed that marijuana can be used as a medication, while 12% (62) were unsure and 7% (33) felt that it could not. The majority of patients felt that marijuana could be used to treat both pain (78%, 390) and anxiety (62%, 309) (Figure 3). In a multiple regression analysis, older patients were found less likely to believe that marijuana was a useful medication (OR 0.97 per year, p<0.001), could be used to treat pain (OR 0.98 per year, p<0.001), or could be used to treat anxiety (OR 0.97 per year, p<0.001). Sex (p=0.38), type of injury (p=0.08-p=0.38), and the need for surgery (p=0.97) were not predictive of a patient's belief of the usefulness of marijuana as a medical drug. The belief of a patient in the utility of

marijuana as a medication for treating pain or anxiety was not influenced by sex (p=0.26/p=0.63) or the need for surgery (p=0.73/p=0.20). Patients with multiple injuries were less likely to believe that marijuana could be used to treat anxiety (OR 0.42, p=0.01) compared to those with isolated lower extremity fractures.

Of the 500 patients who completed the questionnaires, the majority (60%, 302) of them have used marijuana at least once previously. A significantly lower number, 21% (107) reported that they used marijuana in the past year. Only 13.6% reported using marijuana during their recovery from their musculoskeletal injury either often (36 patients, 7.2%) or not often (32 patients, 6.4%). Of those that used marijuana during their recovery, 90% (63/70) believed that it reduced symptoms of pain; and 81% (57/70) believed that it reduced the amount of opioid pain medication they required (Figure 4). In patients that used marijuana, neither age (p=0.10), sex (p=1.0), injury (p=0.57), nor need for surgery (p=0.08), were significantly associated with a perceived reduction in pain level. In patients that used marijuana, neither age (p=0.21), sex (p=0.20), injury (p=0.60), nor need for surgery (p=0.25), were significantly associated with a perceived reduction in the need for prescription pain medication.

The median anxiety PROMIS score was 47 (range 40-81). This indicates that our patients with musculoskeletal trauma are similar to US population norms in terms of feelings of anxiety. Patients who used marijuana during their recovery had greater feelings of anxiety than those who did not (54.3 vs. 48.8, p<0.001). A total of 107 patients (21%) had a clinically relevant score of 40 or more on their Pain Catastrophizing Score (PCS). There was a trend toward patients having increased problems with catastrophic thinking in those that used marijuana during their recovery compared to those that did not (21.1 vs. 17.5, p=0.052). There were 99 patients (20%) who had a score of 4 or more on the PTSD scale, indicating signs of post-traumatic stress disorder. There

was no association between signs and symptoms of PTSD in those that used marijuana during recovery compared to those that did not (80/430 vs. 19/70; 19% p=0.13). There was moderate degree of correlation between patients with higher pain catastrophizing and PROMIS anxiety scores (Spearman correlation coefficient, 0.57), patients with higher pain catastrophizing and PTSD scores (0.55), and higher PROMIS anxiety and PTSD scores (0.58).

The majority, 84%, of respondents indicated that they would be either very comfortable (259), or comfortable (164) discussing medical marijuana with their healthcare provider. However, not as many patients were clear as to the legality of medicinal marijuana use in Massachusetts; 59% (294) of patients correctly knew that marijuana use for medical purposes was legal in Massachusetts. A similar number 55% (273) correctly identified that there were now legal dispensaries currently active. The use of marijuana for medical purposes has been legal in Massachusetts since January 1, 2013, with the first dispensary licensed on December 31, 2014.

Discussion

There has been significant debate within the United States as to the utility of medical marijuana. Despite federal prohibition many states have now passed laws allowing for the prescription of medical marijuana. The American Medical Association (AMA) does not promote or condone the use of medical marijuana but "urges that marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternative delivery methods." It has been our experience that, since the legalization of medical marijuana in Massachusetts, there has been a large increase in the number of patients in our practice inquiring about the utility of using marijuana during their recovery. The goal of this study is to better understand the perceptions of the musculoskeletal patient population with regard to the usefulness of medical marijuana.

While the use, sale, and possession of marijuana is illegal in the United States under
federal law, state laws vary. 13,14 The recreational use of marijuana is currently allowed in 4 states
and Washington DC. Twenty-one additional states have laws allowing for the use of medicinal
marijuana. ¹ In Massachusetts, the use of marijuana for the treatment of medical conditions when
recommended by a physician became legal in January 2013. The first dispensaries were
licensed on December 31st, 2014. Patients with a letter from a physician, and who have registered
with the Department of Public Health (DPH) may grow marijuana for their own consumption
and may possess a 60-day supply as defined by the Department of Public Health, or may legally
purchase marijuana at a dispensary. To prescribe marijuana in the state of Massachusetts a
physician must register with the DPH and must comply with the following criteria: have an
active unrestricted medical license, have a MA controlled substances registration, have at least 1
established location of practice, and complete 2 hours of CME regarding the proper use, side
effects, dosage, contraindications and substance abuse recognition related to marijuana. ¹⁶
Marijuana is the most commonly used illicit drug in the United States. A survey
performed by the Substance Abuse and Mental Health Services Administration in 2001 revealed
that 41.9% of Americans have used marijuana at some point in their lives, while 11.5% have
used marijuana within the last year. 17 A more recent survey, performed by the US Department of
Health and Human Services in 2013 found that 7.6% of Americans aged 18 and over use
marijuana regularly. ² We found a moderately higher rate of marijuana use in our musculoskeletal
trauma population than these studies of national norms (60% use at some point in the past, and
21% in the last year). It is likely that those with a history of illicit drug use and/or recent use are
at higher risk of trauma than the general US population. 18 While there are no officially kept
statistics of the number of patients using medical marijuana, one advocacy group tallied

approximately 1.1 million patients are "registered" to use marijuana in the 25 states with legal medical marijuana. ¹⁹ This accounts for approximately 7.7 people per 1000 state residents.

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

There is limited data available regarding the use of medical marijuana as an analgesic. The highest quality evidence available for the effectiveness of marijuana in pain management has been in the chronic pain patient population. A 2011 systematic review identified 18 randomized clinical trials conducted between 2003 and 2010 evaluating cannabis or cannabinoids for the treatment of non-cancer chronic pain. Fifteen of the 18 trials found a statistically significant, albeit modest, improvement in pain levels in subjects. 20-37 Another beneficial effect of marijuana identified in several of the trials was improved sleep. However, many of these trials were conducted with small samples and the heterogeneity of patient populations and cannabinoid drug delivery makes generalizability difficult. There are 4 small studies looking at the use of medical marijuana in the treatment of neuropathic pain. Two of these deal exclusively with neuropathic pain in HIV patients, and show a benefit to the use of marijuana. ^{20,21} In one study of 23 adults with post-traumatic and post-operative neuropathic pain, the use of medical marijuana demonstrated a decrease in daily pain intensity, improved ability to fall asleep, and improved quality of sleep. 21 Another double-blind, placebo controlled study of 39 patients with chronic neuropathic pain found improved pain scores in patients receiving marijuana. 23 The effect size of marijuana in this study was similar to the published effect size of pregabalin (Lyrica®) and gabapentin (Neurontin®). Together, these 4 studies demonstrate a clear, although small, analgesic effect in patients with neuropathic pain with relatively mild side effects. To our knowledge, there are no direct studies of marijuana in treating post-injury or postoperative pain.

The potential for medicinal marijuana to mitigate the increasing opioid epidemic is a

large potential societal benefit of its use. In 2012, there were 16,007 unintentional deaths due to opioid analgesics (not including heroin) in the United States and since 1999, the age-adjusted rates of opioid-analgesic deaths have more than tripled.³⁸ Studies have shown a correlation between increased medical use/consumption of opioids and opioid-related mortality. ³⁹ A recent study seeking to determine the association of mortality from opioid overdose with medical marijuana legislation has found that states with medical marijuana laws had a 24.8% lower mean annual rate of unintentional opioid overdose mortality compared to states without such legislation. 40 Acute overdose from marijuana alone is extremely uncommon; the estimated fatal dose of marijuana is 15 to 70g, which is well above what even a heavy recreational smoker would ingest. 41 It has been demonstrated that non-medical use of marijuana is not associated with increased non-AIDS mortality at a population-level. 42 The most common drug-related adverse effects with medicinal use of smoked marijuana have been reported to be headache, dry eyes, burning sensation, dizziness, numbness and cough and these side-effects are dosedependent.^{22, 41} Up to 9% of patients who experiment with marijuana can become addicted.⁴³ There is also a clear link between marijuana intoxication and the risk of motor vehicle collisions. 44 Other adverse events that have been associated with marijuana use include exacerbation of mental illness and psychosis, long-term cognitive dysfunction, and possible links to lung cancer, respiratory disease, and cardiovascular disease. 45

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Our study has identified that musculoskeletal trauma patients with recent marijuana use scored higher on the PROMIS anxiety instrument. There was a trend toward higher scores on the Pain Catastrophizing Score. It could be that patients with anxiety and worries are self medicating with marijuana. Conversely, it is possible that marijuana use is related to increased issues with anxiety and pain. There is evidence that marijuana use is increased in patients with mental

illness, although no cause and effect has been identified.⁴⁵ Signs and symptoms of PTSD were similar between those that used marijuana recently and those that did not.

As in any survey this study is limited by patients willingness to respond, and their perceptions. The topic of medical marijuana is controversial, and some people have strong feelings both for and against its use. Anecdotally, we found that patients were open to discussing their beliefs in either direction and the response rate was high (93%). Another limitation is that 31% of patients were treated non-operatively, and this group of patients may under represent the patient perception of improvement of pain control with medical marijuana. This survey also relied upon patient self-reporting in terms of their marijuana use and any effect on pain medications, and thus is potentially subject to reporting bias. Despite these limitations our results are in line with large national polls. In 2011, CBS polled 1025 adults living in the continental United Sates and found that 77% of people thought doctors should be able to prescribe marijuana for a "serious illness." The Hawkeye Poll Cooperative at the University of Iowa conducted a similar poll in 2010, and found that 65% of Americans "favor legalization for medical use." These results are similar to our respondents of whom 73% thought that marijuana was useful as a medicine. Further, 60% of respondents reported using marijuana at some point in their lives, again similar to national polling data reporting 42% lifetime usage.

The role of medical marijuana in managing post-injury and post-operative symptoms of pain and anxiety is poorly understood. The majority of our patients indicated they were comfortable talking with their healthcare provider about medical marijuana. Further, a clear majority of patients in this study believed that medical marijuana is a valid treatment and that it does have a role in reducing post-injury and post-operative pain. Further, in the subset of patients who used marijuana during their recovery, a majority indicated that it helped alleviate symptoms

of pain and reduced their level of opioid intake. Undoubtedly, further investigation is required to parse out associations with the alleviation of pain nociception versus easing of psychological distress that can accompany injury and drive pain perceptions. Patients with recent marijuana use scored higher on the PROMIS anxiety instrument and there was a trend towards an increase in catastrophic thinking. As a cross sectional study, we cannot definitively correlate patients perceptions with an actual improvement in pain or a reduction in opioid use. Pain management should be regarded in a holistic manner and non-pharmacological measures such as coping strategies and development of self-efficacy also need to be explored further in the research. However, our results support further study into the utility of medical marijuana as a pain management adjunct in the orthopaedic trauma population.

241

231

232

233

234

235

236

237

238

239

240

242 References

- 1. National Conference of State Legislatures. State medical marijuana laws.
- 244 http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Published March 16,
- 245 2015. Accessed March 30, 2015.
- 2. United States Department of Health and Human Services Substance Abuse and Mental Health
- Services Administration, Center for Behavioral Health Statistics and Quality. (2014). The
- 248 NSDUH Report: Substance Use and Mental Health Estimates from the 2013 National Survey on
- 249 Drug Use and Health: Overview of Findings. Rockville, MD.
- 3. Cerda M, Wall M, Keyes KM, et al. Medical marijuana laws in 50 states: Investigating the
- relationship between state legalization of medical marijuana and marijuana use, abuse and
- 252 dependence. Drug Alcohol Depend. 2012 Jan 1;120(1-3):22-7.

- 4. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of
- cannabis and cannabinoids. *Anaesthesia*. 2001; 56: 1059-1068.
- 5. Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006;
- 256 8(4): E693-708.
- 6. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug
- 258 Targets. 2009; 8: 403-421.
- 7. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic
- review of randomized trials. Br J Clin Pharmacol. 2011; 72(5): 735-744.
- 8. Pilkonis PA, Choi SW, Reise SP, et al. Item banks for measuring emotional distress from the
- 262 Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety,
- and anger. Assessment. 2011 Sep;18(3):263-83.
- 9. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and
- 265 validation. Psychol Assess. 1995;7:524–32. PubMed PMID: 1996007788.
- 10. Breslau N, Peterson EL, Kessler RC, et al. Short Screening Scale for DSM-IV Posttraumatic
- 267 Stress Disorder. Am J Psychiatry 1999; 156:908–911.
- 268 11. R Core Team (2014). R: A language and environment for statistical computing. R
- Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
- 270 12. American Medical Association. H-95.952 Cannabis for Medicinal Use. https://www.ama-
- assn.org/ resources/html/PolicyFinder/policyfiles/HnE/H-95.952.HTM. Published November 10,
- 272 2009. Accessed March 31, 2015.
- 273 13. Controlled Substances Act, Title 21 U.S.C. §802, 811 (1970).
- 274 14. Gonzales v. Raich, 545 U.S. 1 (2005).
- 275 15. An Act for the Humanitarian Medical Use of Marijuana, M.S.L. ch. 369 §1-17 (2012).

- 276 16. The Commonwealth of Massachusetts, Department of Public Health. Guidance for
- 277 Physicians Regarding the Medical Use of Marijuana, Revised August 21, 2014.
- 278 http://www.mass.gov/eohhs/dph/docs/quality/medical-marijuana/physician-guidance-2014-8-
- 279 21.pdf. Published August 21, 2014. Accessed March 31, 2015
- 280 17. United States Department of Health and Human Services Substance Abuse and Mental
- Health Services Administration, Office of Applied Studies. (2001). National Household Survey
- on Drug Abuse. Ann Arbor, MI.
- 283 18. Rivara FP, Mueller BA, Fligner, et al. Drug use in trauma victims. J Trauma. 1989
- 284 Apr;29(4):462-70.
- 285 19. ProCon.org. Number of Legal Medical Marijuana Patients (as of Oct. 27, 20140).
- 286 http://medicalmarijuana.procon.org/view.resource.php?resourceID=005889. Published October
- 287 14, 2014. Accessed March 31, 2015.
- 288 20. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in
- 289 HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology*. 2009;34:672-80.
- 290 21. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory
- 291 neuropathy: a randomized placebo-controlled trial. *Neurology*. 2007 Feb 13;68(7):515-21.
- 292 22. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a
- 293 randomized controlled trial. CMAJ 2010 Oct 5;182(14):E694-701. doi: 10.1503/cmaj.091414.
- 294 Epub 2010 Aug 30.
- 295 23. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial
- of cannabis cigarettes in neuropathic pain. *J Pain* 2008;9:506-21.

- 24. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and
- safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid
- 299 arthitis. *Rheumatology (Oxford)*. 2006 Jan;45(1):50-2. Epub 2005 Nov 9.
- 300 25. Rog DJ, Numikko TJ, Friede T, et al. Randomized controlled trial of cannabis based
- medicine in central pain due to multiple sclerosis. *Neurology* 2005; 65: 812–19.
- 302 26. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief
- of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled
- 304 trial. Pain 2004; 112: 299-306.
- 305 27. Wade DT, Makela P, Robson P, et al. Do cannabis based medicinal extracts have general or
- 306 specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-
- 307 controlled study on 160 patients. *Mutiple Scler* 2004; 10: 434–41.
- 308 28. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether
- 309 whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;
- 310 17: 21–9.
- 311 29. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain
- 312 characterized by allodynia: a randomized, double-blind, placebo controlled clinical trial. *Pain*
- 313 2007; 133: 210–20.
- 30. Frank B, Serpell MG, Hughes J, et al. Comparison of analgesic effects and patient tolerability
- of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double
- 316 blind study. *BMJ* 2008; 336: 199–201.
- 31. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia.
- 318 *J Pain* 2008; 9: 164–73.

- 32. Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid
- Nabilone significantly reduces spasticity-related pain. *J Neurol* 2006; 253: 1337–41.
- 321 33. Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic
- 322 cannabinomimetic nabilone on patients with chronic pain-a randomized controlled trial. Wein
- 323 Klin Wochenschr 2006; 118: 327–35.
- 324 34. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in
- multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004 Jul
- 326 31;329(7460):253. Epub 2004 Jul 16.
- 327 35. Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for
- 328 chronic pain patients on opioid therapy. *J Pain*. 2008 Mar;9(3):254-64. Epub 2007 Dec 21.
- 329 36. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on
- 330 chronic neuropathic pain. *JAMA* 2003; 290: 1757–62.
- 331 37. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis
- for chronic pain: results from 34 'N of 1' studies. *Anaesthesia* 2004; 59: 440–52.
- 333 38. Warner M, Hedegaard H, Chen L-H. Trends in Drug-poisoning Deaths Involving Opioid
- Analgesics and Heroin: United States, 1999-2012.
- http://www.cdc.gov/nchs/data/hestat/drug_poisoning/drug_poisoning.htm. Published December
- 336 2, 2014. Accessed March 30, 2015.
- 337 39. Oike S. A Flood of Opioids, a Rising Tide of Deaths. N Engl J Med. 2010 Nov
- 338 18;363(21):1981-5. doi: 10.1056/NEJMp1011512.
- 40. Bachhuber MA, Saloner B, Cunningham CO, et al. Medical Cannabis Laws and Opioid
- Analgesic Overdose Mortality in the United States, 1999-2010. *JAMA Intern Med.* 2014
- 341 Oct;174(10):1668-73. doi: 10.1001/jamainternmed.2014.4005.

- 342 41. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet*. 2009 Oct
- 343 17;374(9698):1383-91. doi: 10.1016/S0140-6736(09)61037-0.
- 344 42. Sidney S, Beck JE, Tekawa IS, et al. Marijuana Use and Mortality. *Am J Public Health*. 1997
- 345 April; 87(4): 585–590.
- 346 43. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of
- transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the
- National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Drug Alcohol*
- 349 Depend 2011;115:120-30.
- 350 44. Brady JE, Li G. Trends in alcohol and other drugs detected in fatally injured drivers in the
- 351 United States, 1999-2010. Am J Epidemiol 2014;179:692-9.
- 352 45. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J
- 353 *Med.* 2014 Aug 28;371(9):879.
- 46. CBS News. 2011, CBS News National Poll: Marijuana and Medical Marijuana. Storrs, CT:
- 355 The Roper Center, University of Conneticut[distributor].
- 356 47. Boehmke FJ, 2013, "Hawkeye Poll Fall 2010",
- 357 http://hdl.handle.net/1902.1/20636UNF:5:B3FviCeGWH07kLQssGSA/w==Hawkeye Poll
- 358 Cooperative[Distributor]V5[Version].
- 360 Figure Legend

359

- 361 Figure 1: Flow chart of patients approached, who completed the survey and those that were
- analysis.
- **Figure 2:** Age distribution of responding cohort.
- 364 **Figure 3:** Percentage of respondents who believe marijuana can be used as a medicine, can treat
- pain, and can be used for anxiety.

366	Figure	4: Percentage of patients who have used marijuana in the past, as well as the reported
367	effect o	of marijuana use on post-injury pain and opioid use.
368 369	Appen	dix A: Survey administered to patients.
370 371 372 373 374 375 376 377	the be	you for taking the time to complete this survey. Please answer each question to est of your ability. Do you believe that marijuana can be used as a medicine? Yes No I do not know. Do you believe that marijuana can help in treating pain?
378 379 380 381		Yes No I do not know.
382 383 384 385 386	3.	Do you believe that marijuana can help to treat anxiety? Yes No I do not know.
387 388 389 390	4.	Would you be comfortable with your doctor talking with you about medical marijuana to help treat your injuries? Yes, very comfortable No. tracertable
391392393		No, uncomfortable No, very uncomfortable
394395396397	5.	Have you ever used marijuana? ☐ Yes ☐ No
398 399 400 401	6.	If yes, have you used marijuana in the last year? Yes No Not applicable to me

402 403	
404	7. Did you use marijuana during your recovery from your injury and, if so, how
405	often?
406	☐ Yes, I used marijuana often
407	Yes, I used marijuana but not often
408	☐ No, I did not use marijuana during my recovery.
409 410	If you answered yes to Question 7, please answer these questions. a. Using marijuana reduced my level of pain:
411	Yes, I very much agree.
412	☐ Yes, I agree.
413	I do not agree and I do not disagree.
414	☐ No, I disagree
415	☐ No, I very much disagree.
416	b. Using marijuana reduced my need for prescription pain medication.
417	Yes, I very much agree.
418	☐ Yes, I agree.
419	☐ I do not agree and I do not disagree.
420	☐ No, I do not agree.
421	☐ No, I strongly disagree.
422	
423	8. Is medical marijuana legal in the state of Massachusetts?
424	Yes
425	□ No
426	☐ I do not know.
427	
428	Is medical marijuana available in the state of Massachusetts?
429	Yes
430	No
431	La I do not know
432	
433	
434	
435	

436	Everyone experiences painful situations at some point in their lives. Such experiences may		
437	include headaches, toothaches, joint or muscle pain. People are often exposed to situations that		
438	may cause pain such as illness, injury, dental procedures, or surgery. We are interested in the		
439	types of thoughts and feelings that you have when you are in pain. Listed below are thirteen		
440	statements describing different thoughts and feelings that may be associated with pain. Using the		
441	following scale, please indicate the degree to which you have these thoughts and feelings when		
442	you are experiencing pain.		
443	you are experiencing pain.		
444	1. When I'm in pain I worry about whether the pain will end		
	1. When the ham I worry about whether the pain will end		
445	Not at all		
446	To a slight degree		
447	To a moderate degree		
448	To a great degree		
449	All the time		
450	All the time		
451	2. When I'm in pain I feel I can't go on		
131	2. When the hipam Free Feart go on		
452	Not at all		
453	To a slight degree		
454	To a moderate degree		
455	To a great degree		
456	All the time		
457	The die chile		
458	3. When I'm in pain It's terrible and I think it's never going to get any better		
459	Not at all		
460	To a slight degree		
461	To a moderate degree		
462	To a great degree		
463	All the time		
464			
465	4. When I'm in pain It's awful and I feel that it overwhelms me		
466	Not at all		
467	To a slight degree		
468	To a moderate degree		
469	To a great degree		
470	All the time		
471			
472	5. When I'm in pain I feel I can't stand it anymore		
450	N 11		
473	Not at all		
474	To a slight degree		
475	To a moderate degree		
476	To a great degree		
477	All the time		
478			

479	6. When I'm in pain I become afraid that the pain will get worse
480	Not at all
481	To a slight degree
482	To a moderate degree
483	To a great degree
484	All the time
485	
486	7. When I'm in pain I keep thinking of other painful events
487	Not at all
488	To a slight degree
489	To a moderate degree
490	To a great degree
491	All the time
492	
493	8. When I'm in pain I anxiously want the pain to go away
494	Not at all
495	To a slight degree
496	To a moderate degree
497	To a great degree
498	All the time
499	
500	9. When I'm in pain I can't seem to keep it out of my mind
501	Not at all
502	To a slight degree
503	To a moderate degree
504	To a great degree
505	All the time
506	
507	10. When I'm in pain I keep thinking about how much it hurts
508	Not at all
509	To a slight degree
510	To a moderate degree
511	To a great degree
512	All the time
513	
514	11. When I'm in pain I keep thinking about how badly Iwant the pain to stop
515	Not at all
516	To a slight degree
517	To a moderate degree
518	To a great degree
519	All the time
520	

521		12. When I'm in pain There's nothing I can do to reduce the intensity of the pain	
522	No	et at all	
523	To	a slight degree	
524	To a moderate degree		
525	To a great degree		
526	All the time		
527			
528		13. When I'm in pain I wonder whether something serious may happen	
529	No	ot at all	
530	To	a slight degree	
531			
532		a great degree	
533		I the time	
534	1 11		
535	Th	ese next questions will ask you about certain situations you may have encountered after your	
536		ury. The "experience" we speak of in these questions refers to your injury.	
537	ш	ary. The experience we speak of in these questions ferers to your injury.	
538		1. Did you avoid being reminded of this experience by staying away from certain places, people, or	
539		activities?	
540		Yes	
541		No	
542		140	
543	2.	Did you lose interest in activities that were once important or enjoyable?	
544	۷.	Yes	
545		No	
546		140	
547	3.	Did you begin to feel more isolated or distant from other people?	
548	٥.	Yes	
549		No	
550		140	
551	4.	Did you find it hard to have love or affection for other people?	
552	т.	Yes	
553		No	
554			
555	5.	Did you begin to feel that there was no point in planning for the future?	
556	٥.	Yes	
557		No	
558			
559	6.	After this experience were you having more trouble than usual falling asleep or staying asleep?	
560	0.	Yes	
561		No	
562			
563	7.	Did you become jumpy or get easily startled by ordinary noises or movements?	
564	/.	Yes	
565		No No	
566		110	
500			

- 1. In the past 7 days, I felt fearful
- 568 Never
- 569 Rarely
- 570 Sometimes
- 571 Often
- 572 Always

573

- 574 2. In the past 7 days. I found it hard to focus on anything other than my anxiety
- 575 Never
- 576 Rarely
- 577 Sometimes
- 578 Often
- 579 Always

580

- 3. In the past 7 days, my worries overwhelmed me
- 582 Never
- 583 Rarely
- 584 Sometimes
- 585 Often
- 586 Always

587

- 588 4. In the past 7 days, I felt uneasy
- 589 Never
- 590 Rarely
- 591 Sometimes
- 592 Often
- 593 Always

Table

Table 1. Patient demographic information and injury characteristics.

Variable	Total Cohort (n=500)
Age	
median (range) yrs	55 (18-93)
Sex	
Female (%)	250 (50%)
Male (%)	250 (50%)
Treatment	
Surgical	347 (69%)
Non-Operative	153 (31%)
Pelvis/Lower Extremity	334 (67%)
Upper Extremity Fracture	101 (20%)
Multiple Fractures	49 (10%)
Soft Tissue Injuries	16 (3%)











